Showing 1-10 of 13 results for "".
- XBiotech Adds Dr. Alice Gottlieb to its Scientific Advisory Boardhttps://practicaldermatology.com/news/xbiotech-adds-dr-alice-gottlieb-to-its-scientific-advisory-board/2457599/Alice Gottlieb, MD, PhD joined XBiotech Inc.'s Scientific Advisory Board (SAB). Dr. Alice Gottlieb is internationally recognized for her expertise and pioneering work in the development of biological therapies to treat skin diseases. Dr. Gottlieb has played key roles in the clinical evaluation of t…
- Dr. Alice Gottlieb to Share Hidradenitis Suppurativa Findings at AAD Annual Meetinghttps://practicaldermatology.com/news/dr-alice-gottlieb-to-share-hidradenitis-suppurativa-findings-at-aad-annual-meeting/2459916/Alice Gottlieb, MD, PhD will be presenting “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on March 2, 2019 at the American Academy of Dermatology annual meeting being held at the Walter E. Washington Convention…
Benchside Dispatches Psoriasis
https://practicaldermatology.com/topics/psoriasis/benchside-dispatches-psoriasis/20922/An interview with Alice Gottlieb, MD, PhDOff-label Uses for Biologics
https://practicaldermatology.com/topics/psoriasis/off-label-uses-for-biologics/18964/Derm Insider Bonus Content: Host Neal Bhatia speaks with guests Alice Gottlieb, MD, Harold Farber, MD, and James Ulery, MD about various potential off-label uses for current and investigational systemic psoriasis therapies.Part 3: New Developments in Biologics
https://practicaldermatology.com/topics/psoriasis/part-3-new-developments-in-biologics/18965/In this edition of Derm Insider, host Neal Bhatia, MD tackles the evolving systemic treatment landscape for psoriasis with guests Alice Gottlieb, MD, Harold Farber, MD, and James Ulery, MD. In Part III, they discuss new developments in biologic therapy.- Medical Professionals, Practical Dermatology® Board Members, Recognized for Outstanding Work in Psoriatic Disease Fieldhttps://practicaldermatology.com/news/medical-professionals-practical-dermatology-board-members-recognized-for-outstanding-work-in-psoriatic-disease-field/2458661/Nominated by patients and colleagues, recipients of the first annual National Psoriasis Foundation Medical Professionals Awards exemplify the outstanding work being done in the psoriatic disease community. Selected by a committee of National Psoriasis Foundation (NPF) medical board and leadersh…
- NPF Update: Group Hosts 25th Dermatology Residents’ Meeting and Research Symposium: A Cure for Allhttps://practicaldermatology.com/news/npf-update-group-hosts-25th-dermatology-residents-meeting-and-research-symposium-a-cure-for-all/2462049/The National Psoriasis Foundation (NPF) celebrated the 25th anniversary of the annual Dermatology Residents’ Meeting on October 7 and 8, 2023 in Washington, D.C. Experts and co-chairs Brad P. Glick, DO, MPH, FAAD, and Samuel Hwang MD, PhD. hosted the silver anniversary event with 100 attendees sel…
- FDA Approves Cimzia for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-cimzia-for-moderate-to-severe-plaque-psoriasis/2457747/The FDA has approved extending the label for UCB's Cimzia (certolizumab pegol) to include a new indication in adults with moderate to severe plaque psoriasis. Cimzia is indicated for the treatment of adults with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or ph…
- Deucravacitinib Shows Sustained Response, Safety Profile: Analyseshttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-response-safety-profile-analyses/2462221/Deucravacitinib (SOTYKTU, Bristol Myers Squibb) is a first-in-class, oral, selective allosteric TYK2 inhibitor, and has been approved in the United States, European Union, and other countries for use in adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Two abs…
- FDA Proposes New Sunscreen Regulations; Experts Reacthttps://practicaldermatology.com/news/fda-proposes-new-sunscreen-regulations-experts-react/2459889/The FDA is updating its position on over-the-counter sunscreens, and according to the new proposal, several popular ingredients require more data. New guidelines do, however, note that zinc oxide and titanium oxide remain safe to use. The FDA evaluated a total of 16 sunscreen ingredients and found …
- Prev
- Next